TG Therapeutics (NASDAQ:TGTX) Price Target Raised to $55.00

TG Therapeutics (NASDAQ:TGTX) had its target price raised by HC Wainwright from $49.00 to $55.00 in a research note issued to investors on Tuesday,Benzinga reports. HC Wainwright currently has a buy rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for TG Therapeutics’ Q4 2024 earnings at $0.15 EPS, FY2024 earnings at $0.07 EPS, FY2025 earnings at $1.17 EPS and FY2026 earnings at $1.77 EPS.

A number of other research analysts have also recently commented on the company. The Goldman Sachs Group boosted their price objective on TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research note on Tuesday. TD Cowen assumed coverage on TG Therapeutics in a research note on Tuesday, October 29th. They set a “buy” rating and a $50.00 price objective on the stock. Finally, B. Riley boosted their price objective on TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $37.67.

TG Therapeutics Price Performance

Shares of TG Therapeutics stock opened at $27.90 on Tuesday. TG Therapeutics has a twelve month low of $9.81 and a twelve month high of $28.41. The stock has a market capitalization of $4.32 billion, a P/E ratio of -278.97 and a beta of 2.19. The company has a current ratio of 3.58, a quick ratio of 2.83 and a debt-to-equity ratio of 0.58. The business’s fifty day moving average price is $23.73 and its 200 day moving average price is $20.36.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.65%. The firm had revenue of $83.90 million during the quarter, compared to analyst estimates of $81.68 million. During the same quarter in the previous year, the business posted $0.73 EPS. TG Therapeutics’s revenue was down 49.4% compared to the same quarter last year. As a group, research analysts anticipate that TG Therapeutics will post 0.13 earnings per share for the current year.

Institutional Trading of TG Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of TGTX. Swiss National Bank increased its position in shares of TG Therapeutics by 0.5% during the first quarter. Swiss National Bank now owns 284,100 shares of the biopharmaceutical company’s stock worth $4,321,000 after acquiring an additional 1,500 shares during the last quarter. Quantum Private Wealth LLC increased its position in shares of TG Therapeutics by 13.7% during the first quarter. Quantum Private Wealth LLC now owns 103,604 shares of the biopharmaceutical company’s stock worth $1,576,000 after acquiring an additional 12,523 shares during the last quarter. Sei Investments Co. purchased a new stake in shares of TG Therapeutics during the first quarter worth about $591,000. Russell Investments Group Ltd. increased its position in shares of TG Therapeutics by 133.5% during the first quarter. Russell Investments Group Ltd. now owns 52,339 shares of the biopharmaceutical company’s stock worth $796,000 after acquiring an additional 29,923 shares during the last quarter. Finally, ProShare Advisors LLC increased its position in shares of TG Therapeutics by 8.5% during the first quarter. ProShare Advisors LLC now owns 24,914 shares of the biopharmaceutical company’s stock worth $379,000 after acquiring an additional 1,961 shares during the last quarter. 58.58% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.